GlassScriptPhysician profile
Andrew H Rogness
NPI 1760588446
$4,077.86
in general payments reported to CMS, 2019-2025
31 companies · $666 in 2025
The $666 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $225 · 2021: $610 · 2022: $561 · 2023: $641 · 2024: $816 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,589.63 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Mylan Specialty L.P. | $548.43 | 2019-2024 | Yupelri |
| Grifols USA, LLC | $411.78 | 2020-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $257.21 | 2021-2025 | Ofev |
| Electromed, INC. | $183.56 | 2022-2025 | Smartvest |
| Viatris Specialty LLC | $170.50 | 2025 | Yupelri |
| Mallinckrodt Hospital Products INC. | $140.28 | 2021-2024 | Acthar |
| Astrazeneca Pharmaceuticals LP | $110.30 | 2020-2023 | Tezspire |
| Novartis Pharmaceuticals Corporation | $94.63 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $60.98 | 2019-2023 | Uptravi |
| Regeneron Healthcare Solutions, INC. | $57.28 | 2021-2024 | Dupixent |
| Jazz Pharmaceuticals INC. | $45.96 | 2021-2025 | |
| Genzyme Corporation | $44.15 | 2022-2025 | |
| Inari Medical, INC. | $41.48 | 2022-2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Bayer Healthcare Pharmaceuticals INC. | $31.13 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $30.15 | 2021-2022 | |
| Pfizer INC. | $24.06 | 2019-2022 | |
| Axsome Therapeutics, INC. | $23.97 | 2023 | Sunosi |
| Amgen INC. | $21.89 | 2023 | Tezspire |
| Merck Sharp & Dohme LLC | $19.91 | 2024 | Zerbaxa, Recarbrio |
| Sunovion Pharmaceuticals INC. | $19.35 | 2020 | |
| Abbvie INC. | $18.45 | 2023 | Teflaro |
| Genentech USA, INC. | $17.81 | 2021 | |
| Pulmonx Corporation | $17.40 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Chartis Catheter |
| Takeda Pharmaceuticals U.S.A., INC. | $15.65 | 2020 | |
| Harmony Biosciences LLC | $15.35 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $14.55 | 2024 | Lumryz |
| Boston Scientific Corporation | $13.98 | 2022 | |
| Shionogi INC | $13.18 | 2023 | Fetroja |
| Circassia INC. | $12.49 | 2019 | |
| United Therapeutics Corporation | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Rogness listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.